δ-like 1

ORL1 antagonist 1 is an o antagonist of pioid receptor-like 1 (ORL1) (IC50 of 61 nM).

JTC-801 is a selective opioid receptor-like 1 (ORL1) receptor antagonist with an IC50 of 94 nM and weak inhibitory effects on δ, κ, and μ receptors.

Nociceptin (1-7) acetate is a potent agonist of opioid receptor-like 1 (ORL1) receptor. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia and has antinociceptive activity.

Nociceptin (1-13), amide is a potent ORL1 (OP4) receptor agonist, exhibiting a pEC50 of 7.9 in mouse vas deferens and a Ki of 0.75 nM for rat forebrain membrane binding.

Nociceptin (1-13), amide is a potent agonist Opioid receptor-like1 (ORL1) receptor with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) is an IgG, κ inhibitor antibody derived from the American hamster, targeting mouse δ-like protein 1/DLL1.

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide biotinylated at the C-terminal.

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide, a biotin-labeled variant of glucagon-like peptide-1-(7-36), is a gastrointestinal peptide known for its antidiabetogenic properties, including enhancing insulin secretion [1] [2].

Glucagon-like peptide 1 (1-37), human (TFA), is a highly potent agonist of the GLP-1 receptor and is a pancreatic hormone synthesized through post-translational processing of proglucagon.

Glucagon-like peptide 1 (1-37), human, is a highly potent agonist of the GLP-1 receptor and a pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it neither affects food intake in rats nor enhances pancreatic insulin secretion.

Glucagon-like peptide 1 (1-37), human acetate is a highly potent the GLP-1 receptor agonist.

Bombinin-Like Peptide (BLP-1) is an antimicrobial peptide derived from species of the genus Bombina.

PAL-4 stimulates the activity of LYPLAL1, a poorly characterized serine hydrolase with complex genetic links to human metabolic traits.

BW373U86 (SNC86), a δ-opioid receptor agonist, demonstrates potent activity with an IC50 value of 1.49 nM and has shown to exhibit antidepressant-like effects [1].

SB-612111 is a novel and potent human opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki = 0.33 nM). It exhibits selectivity for μ-, κ-, and δ-receptors with Ki values of 57.6 nM, 160.5 nM, and 2109 nM, respectively. SB-612111 effectively antagonizes the pronociceptive action of Nociceptin in an acute pain model[1].

(Rac)-SNC80, a racemate of SNC80 (NIH 10815), is a potent, highly selective non-peptide δ-opioid receptor agonist, characterized by a K_i of 1.78 nM and an IC_50 of 2.73 nM. Demonstrating antinociceptive, antihyperalgesic, and antidepressant-like effects, SNC80 holds potential for the treatment of multiple headache disorders [1] [2] [3] [4] [5] [6].

UFP-101 TFA is a potent, selective, and competitive N/OFQ peptide (NOP) receptor antagonist with a pKi value of 10.24, showing over 3000-fold selectivity against δ, μ, and κ opioid receptors, and exhibits antidepressant-like effects [1] [2].